Abstract
Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 44-49 |
Numero di pagine | 6 |
Rivista | Breast Care |
Volume | 10 |
Numero di pubblicazione | 1 |
DOI | |
Stato di pubblicazione | Pubblicato - 6 apr 2015 |
Pubblicato esternamente | Sì |